New insider activity at Fulgent Genetics ( (FLGT) ) has taken place on September 3, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Fulgent Genetics stock, President & COO Jian Xie sold 1,128 shares, amounting to $24,838. Additionally, CSO Hanlin Gao sold 1,063 shares, with the sale totaling $23,407.
Recent Updates on FLGT stock
In the last 24 hours, Fulgent Genetics has experienced notable developments in its stock evaluation. UBS upgraded Fulgent Genetics to a Buy rating, raising the price target from $20 to $30. This upgrade is attributed to the potential for growth in the company’s Precision Diagnostics unit, which accounts for 60% of total sales, due to opportunities for market share gains and a more favorable reimbursement landscape. Additionally, the recovery of Fulgent’s Anatomic Pathology segment, which is no longer dilutive to growth, supports this positive outlook. UBS anticipates the company will sustain a 10% revenue growth rate in 2025 and beyond. Conversely, Piper Sandler lowered its price target from $23 to $21 following the company’s quarterly results, maintaining a Neutral rating. These mixed evaluations reflect differing perspectives on Fulgent’s recent financial performance and growth prospects.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Fulgent Genetics’ overall stock score is driven by strong technical indicators and positive earnings call highlights, such as revenue growth and product expansion. However, financial performance challenges, particularly in profitability and cash flow, and a negative valuation score due to losses, weigh down the overall score.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
YTD Price Performance: 21.12%
Average Trading Volume: 268,189
Technical Sentiment Signal: Hold
Current Market Cap: $678.6M